Table 1.
Intraductal Administration of Pegylated Liposomal Doxorubicin (PLD) Into Ductal Carcinoma In Situ Duct (DCIS) Containing Ducts
| Subject No. | Cannulation | Dose Doxil | Adverse Effects |
|---|---|---|---|
| 001 | Technical difficulties | — | — |
| 002 | Correct duct | 20 mg | Tenderness and erythema (d 23) |
| 003 | Adjacent duct | 4 mg | — |
| 004 | Duct not found | N/A | N/A |
| 005 | Perforated | N/A | N/A |
| 006 | Correct duct | 20 mg | None |
| 007 | Correct duct | 20 mg | Tenderness, erythema (24 h) |
| 008 | Perforated | N/A | N/A |
| 009 | Correct duct | 20 mg | Slight tenderness d 10–20 |
| 010 | Perforated | N/A | N/A |
| 011 | Correct duct | 20 mg | None |
| 012 | Could not cannulate | N/A | N/A |
| 013 | Correct duct | Saline solution | None |
Abbreviation: N/A = not applicable.